No Benefit of Enteric-Coated Aspirin vs Uncoated in CVD

There is no decrease in efficacy but no significant benefit of enteric-coated aspirin over uncoated aspirin in patients with cardiovascular disease, post hoc results of the ADAPTABLE trial suggest.

Related Keywords

Amber Sleem ,Ochsner Medical Center ,Department Of Medicine ,Outcomes Research Institute ,Aspirin Dosing ,Patient Centric Trial Assessing Benefits ,Long Term Effectiveness ,New Orleans ,Patient Centered Outcomes Research ,Cv ,Ardiovascular ,Aspirin ,Stroke ,Erebrovascular Accident ,Va Cerebrovascular Accident ,Myocardial Infarction ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Cardiovascular Disease ,Vd Cardiovascular Disease ,Atherosclerotic Heart Disease ,Therosclerotic Cardiovascular Disease ,Oronary Heart Disease ,Schemic Heart Disease ,Athemo ,